^
Association details:
| Biomarker: | ALK-HLA-DRB1 fusion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Zykadia (ceritinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Case Report: Patient With Lung Adenocarcinoma With ALK-HLA-DRB1 Rearrangement Shows Impressive Progression-Free Survival After Sequential Crizotinib and Ceritinib Treatment
Published date:
02/25/2022
Excerpt:
...we describe a case of advanced lung adenocarcinoma harboring a rare ALK-HLA-DRB1 (major histocompatibility complex, class II, DR beta 1) gene fusion. The patient achieved a rapid and remarkable response after crizotinib treatment. For economic reasons, 6 months later the patient was switched to receiving oral ceritinib, and she responded well. As of this writing, the progression-free survival of this patient is more than 18 months.
DOI:
https://doi.org/10.3389/fonc.2022.762338
